The Advanced Industries Accelerator (AIA) Program announced that 22 Colorado companies and five researchers were approved to receive Proof of Concept and Early Stage Capital and Retention grants for a total of $6,350,918 million in funding. GelSana Therapeutics, Inc. is one of the 22 companies that will receive an award. Proof-of-Concept grants are open to certified Colorado research universities and federal labs located in Colorado for pre-commercialization research and commercialization preparation. Early Stage Capital and Retention grants fund early stage companies commercializing innovative technologies to create viable products that meet a market need and can be created or manufactured in Colorado and exported globally. The AIA Program received 106 applications this grant cycle. Applications were reviewed in a multi-stage review process by committees of business, technical and financial experts in the seven advanced industries. Final recommendations were approved by the Economic Development Commission on November 18, 2021. 

Read More…